跳至主要内容
临床试验/EUCTR2018-000398-64-ES
EUCTR2018-000398-64-ES进行中(未招募)1 期

Patterns of uptake of 18F-FDG and 68Ga-DOTA PET in advanced neuroendoctrine tumors

Vall d' Hebron Institute of Oncology (VHIO)0 个研究点目标入组 30 人开始时间: 2018年4月20日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • The study population will be composed of 30 patients with metastatic NET. A total of 15 patients with primary pancreatic tumor and 15 with primary extra-pancreatic tumor will be included.
  • 1. Age > 18 years.
  • 2. Signed informed consent form.
  • 3. Grade 1 and 2 NETs according to WHO and ENETS classification.
  • 4. Metastatic NETs.
  • 5. Life expectancy > 12 months.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • 1. Grade 3 NET according to WHO and ENETS classification.
  • 2. Previous systemic radiopharmaceutical therapy.
  • 4. Pregnancy
  • 5. High-risk disease (cardiovascular, pulmonary...)
  • 6. Chronic liver disease

研究者

发起方
Vall d' Hebron Institute of Oncology (VHIO)

相似试验